1Centers for Disease Control and Prevention (CDC). Increases in gonorrhea-eight western states, 2000-2005. MMWR Morb Mortal Wldy Rep, 2007, 56( 10):222-225.
2Zwahlen M, Spoerri A Gebhardt M, et al Surveillance systems for sexually transmitted diseases in Switzerland, Sex Transm Dis, 2007, 34(2): 76-80.
3Martin IM, Hoffmann S, Ison CA, et al. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe. J Antimicrob Chemother, 2006, 58(3):587.
4Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep, 2007, 56( 14): 332-336.
5Aplasca De Los Reyes MR, Pato-Mesola V, Klausner JD, et al. A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. Clin Infect Dis, 2001, 32(9): 1313-1318.
6Woods CR. Gonococcal infections in neonates and young children. Semin Pediatr Infect Dis, 2005, 16(4): 258-270.
7Centers For Diease Control and Prevention (CDC). 2002 Guidelines for treatment of sexually transmitted diseases. MMWR, 2002,51(6): 32-35.
8Babl FE, Ram S, Barnett ED, et al. Neonatal gonococcal arthritis after negative prenatal screening and despite conjunctival prophylaxis. Pediatr Infect Dis J, 2000, 19(4): 346.
9Roy K, Wang SA, Meltzer MI. Optimizing treatment of antimicrobial-resistant Neisseria gonorrhoeae. Emerg Infect Dis, 2005, 11(8): 1265-1273.
10Tyson M. Guidance for first-line treatment of anogenital gonorrhoea infection. Br J Nuts, 2005, 14( 12): 646-652.
